نتایج جستجو برای: pd l2

تعداد نتایج: 79105  

2017
Cinzia Solinas Soizic Garaud Pushpamali De Silva Anaïs Boisson Gert Van den Eynden Alexandre de Wind Paolo Risso Joel Rodrigues Vitória François Richard Edoardo Migliori Grégory Noël Hugues Duvillier Ligia Craciun Isabelle Veys Ahmad Awada Vincent Detours Denis Larsimont Martine Piccart-Gebhart Karen Willard-Gallo

There is an exponentially growing interest in targeting immune checkpoint molecules in breast cancer (BC), particularly in the triple-negative subtype where unmet treatment needs remain. This study was designed to analyze the expression, localization, and prognostic role of PD-1, PD-L1, PD-L2, CTLA-4, LAG3, and TIM3 in primary BC. Gene expression analysis using the METABRIC microarray dataset f...

2015
Maria-Victoria Mateos David Siegel Jatin J Shah Donna Reece David Avigan Robert Orlowski Yang Ge Arun Balakumaran Patricia Marinello Jesus San Miguel

Background The immunomodulatory drug (IMiD) lenalidomide has single-agent activity against RRMM, and synergistic effects when combined with dexamethasone. Overexpression of PD-L1 is associated with tumor invasiveness in MM cells and may be a mechanism of immune evasion. Pembrolizumab, a highly selective, humanized IgG4 anti-PD-1 monoclonal antibody designed to block interaction of PD-1 with PD-...

2017
Takayuki Hirose Yuka Tanaka Asuka Tanaka Hiroshi Sakai Yu Sasaki Nobuo Shinohara Hideki Ohdan

B cells constitute a complex system of antigen-presenting cells (APCs) and exist as distinct subsets that differ in their lineage affiliation, surface molecule expression, and biological function, thus potentially regulating the immune response. In this study, we investigated the immune-regulatory roles of murine B cell subsets as regulatory APCs targeting alloreactive T cells. Either splenic B...

2016
Semir Vranic Nilanjan Ghosh Jeffery Kimbrough Nurija Bilalovic Ryan Bender David Arguello Yvonne Veloso Aida Dizdarevic Zoran Gatalica

Targeted immunotherapy based on PD-1/PD-L1 suppression has revolutionized the treatment of various solid tumors. A remarkable improvement has also been observed in the treatment of patients with refractory/relapsing classical Hodgkin lymphoma (cHL). We investigated PD-L1 status in a variety of treatment resistant lymphomas. Tumor samples from 78 patients with therapy resistant lymphomas were im...

2016
Andrew S. Flies A. Bruce Lyons Lynn M. Corcoran Anthony T. Papenfuss James M. Murphy Graeme W. Knowles Gregory M. Woods John D. Hayball

The devil facial tumor disease (DFTD) is caused by clonal transmissible cancers that have led to a catastrophic decline in the wild Tasmanian devil (Sarcophilus harrisii) population. The first transmissible tumor, now termed devil facial tumor 1 (DFT1), was first discovered in 1996 and has been continually transmitted to new hosts for at least 20 years. In 2015, a second transmissible cancer [d...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید